Sandoz, a global leader in generic and biosimilar medicines, is driven by its purpose to pioneer access for patients. With a rich heritage of over 130 years, Sandoz was spun off from Novartis in October 2023 to become a standalone, publicly traded company. Sandoz International GmbH is a key operational entity within this global structure. The company develops, manufactures, and markets a broad portfolio of high-quality, affordable medicines across a wide range of therapeutic areas, aiming to improve healthcare accessibility and sustainability worldwide. Sandoz is committed to innovation, quality, and meeting unmet medical needs.
Serves as a key operational hub, housing management for Sandoz's German operations, as well as various global and European central, scientific, and administrative functions.
Modern office and potentially research facilities designed to support advanced pharmaceutical operations and collaborative work.
A dynamic and science-driven environment, fostering collaboration, innovation, and a commitment to quality. The culture reflects Sandoz's global values of pioneering access, acting with integrity, and driving sustainable growth, within a German operational context.
A vital site for Sandoz in Europe, central to its presence in the German market—one of the largest pharmaceutical markets in Europe—and supporting broader European and global functions for the Sandoz group.
As part of the global Sandoz network, Sandoz International GmbH contributes to a worldwide presence spanning over 100 countries. Sandoz globally supports functions including research and development, manufacturing, quality assurance, supply chain management, commercial operations, and patient access programs. This extensive network allows Sandoz to deliver a broad portfolio of generic and biosimilar medicines to patients around the world.
Industriestraße 25
Holzkirchen
Bavaria
Germany
Address: Lichtstrasse 35, 4056 Basel, Switzerland
Serves as the central decision-making hub for Sandoz's worldwide operations in the generics and biosimilars industry.
Address: 100 College Road West, Princeton, NJ 08540, USA
Key hub for Sandoz's operations in North America, one of the largest pharmaceutical markets globally, focusing on delivering generic and biosimilar medicines to American patients.
Address: Biochemiestrasse 10, 6250 Kundl, Austria
Critical node in Sandoz's global manufacturing network, ensuring supply of essential medicines and driving innovation in production technologies for antibiotics and complex biosimilars.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Sandoz International GmbH' leadership includes:
Sandoz International GmbH has been backed by several prominent investors over the years, including:
Following the spin-off from Novartis in October 2023, Sandoz established its new independent executive leadership team. The primary 'new hires' at the executive level were the appointments to the Sandoz Executive Committee (SEC) to lead the standalone company. No major high-profile exits from this newly formed team have been publicly announced shortly after its formation.
Discover the tools Sandoz International GmbH uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Sandoz commonly uses the firstname.lastname@sandoz.com email format for its employees. This is a standard pattern for many global corporations, facilitating professional communication.
firstname.lastname@sandoz.com
Format
jane.doe@sandoz.com
Example
90%
Success rate
Sandoz Official Website • May 7, 2024
Sandoz reported strong net sales and core EBITDA growth for the first quarter of 2024, driven by robust performance in both Generics and Biosimilars. The company reiterated its financial guidance for the full year 2024....more
Sandoz Official Website • April 4, 2024
Sandoz announced an agreement to acquire UK-based Coalesce Product Development Limited, a company specializing in the development of respiratory devices. This acquisition aims to enhance Sandoz's capabilities in developing and bringing complex respiratory medicines to patients....more
Sandoz Official Website • October 2, 2023
Sandoz launched its Tyruko® biosimilar (natalizumab) in Germany, making it the first and only biosimilar available for the treatment of relapsing-remitting multiple sclerosis. This launch underscores Sandoz's commitment to expanding patient access to critical biologic medicines....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Sandoz International GmbH, are just a search away.